pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ziihera
drug · antibody
save

zanidatamab

pre_registrationupdated 6mo ago
by $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and biliary tract neoplasm and 4 investigational indications.

targets

Receptor tyrosine-protein kinase erbB-2

all catalysts(0)

nothing on the calendar yet

Trials studying zanidatamab

  • phase2Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spreadrecruitingn=768
  • —Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEAnot yet recruitingn=300
  • phase3Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancerrecruitingn=286
  • phase2Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumabcompletedn=71
  • phase3A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancersactive not recruitingn=920
  • phase2Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinomarecruitingn=168
  • phase2AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomasrecruitingn=242
  • phase2A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancerrecruitingn=125

News(10)

  • 6 potential blockbusters that could pave China’s path to 2030 ambitions
    In its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…
    biospace · 13d ago
  • Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
    Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.
    biospace · 24d ago
  • Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
    Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
    biospace · 1mo ago
  • Beyond China: Five other overseas destinations for biopharma dollars
    As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.
    biospace · 2mo ago
  • UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy
    Plus, news about Regeneron, Novocure, Jazz's Ziihera, BioMarin, Ascendis, AstraZeneca, Hutchmed and TScan Therapeutics. Another road bump for Tavneos: The Medicines and Healthcare products Regulato…
    endpoints · 2mo ago
  • Roche nabs expanded FDA approval for diagnostic tied to Jazz’s cancer drug
    Roche has been given an extended clearance by the FDA for its tests that can find patients eligible to use Jazz Pharmaceuticals’ oncology med Ziihera.
    fiercebiotech · 2mo ago
  • Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
    Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
    biospace · 2mo ago
  • New Jazz cancer drug approval could drive blockbuster sales
    Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
    biopharma_dive · 2mo ago
  • FDA approves Jazz's Ziihera in frontline gastric cancer
    Jazz Pharmaceuticals’ bispecific antibody Ziihera won a label expansion to treat certain patients with gastric cancer. It’s the first time Ziihera will be marketed to newly diagnosed patients, foll…
    endpoints · 2mo ago
  • Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 2mo ago
view all news mentions →
brand
Ziihera
trade names
Ziihera
generic
zanidatamab-hrii
MOA
Receptor protein-tyrosine kinase erbB-2 inhibitor
indication
Adenocarcinoma Of The Gastroesophageal Junction
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?